Unlocking LAG3: Ubiquitin's unexpected role.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 40315815.
- Also identified by DOI 10.1016/j.cell.2025.03.030.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The inhibitory receptor LAG3 is the target of the FDA-approved mAb relatlimab, but its mechanism of signaling is not well understood. In this issue of Cell, Jiang et al. demonstrate that ubiquitination of its cytoplasmic domain is essential for the inhibitory function of LAG3. Co-expression of LAG3 and the CBL E3 ligases represents a biomarker of clinical response to LAG3 inhibition in human melanoma.
Medical subject headings
- Ubiquitin